Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 23, No. 2, 2007
Issue release date: January 2007
Section title: Original Research Article
Dement Geriatr Cogn Disord 2007;23:67–73

Depression in Vascular Dementia Is Quantitatively and Qualitatively Different from Depression in Alzheimer’s Disease

Park J.H.a · Lee S.B.a · Lee T.J.a · Lee D.Y.d, e · Jhoo J.H.f · Youn J.C.c · Choo I.H.d · Choi E.A.a · Jeong J.W.a · Choe J.Y.a · Woo J.I.d, e · Kim K.W.a, b, e
aDepartment of Neuropsychiatry and bStroke Center, Seoul National University Bundang Hospital, and cDepartment of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Gyeonggido, dDepartment of Neuropsychiatry, Seoul National University Hospital, and eSeoul National University College of Medicine, Seoul, and fDepartment of Neuropsychiatry, Kangwon University College of Medicine, Kangwondo, Korea
email Corresponding Author

Ki Woong Kim, MD, PhD

Department of Neuropsychiatry, Seoul National University College of Medicine and

Seoul National University Bundang Hospital

300 Gumidong, Bundanggu, Seongnamsi, Gyeonggido 463-707 (Korea)

Tel. +82 31 787 7432, Fax +82 31 787 4058, E-Mail kwkimmd@snu.ac.kr

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background/Aims: To compare the prevalence and characteristics of depression in vascular dementia (VaD) and Alzheimer’s disease (AD) after adjusting for dementia severity and gender. Methods: One hundred and eight pairs of VaD and AD patients matched for dementia severity and gender were assessed. Results: Major depressive disorder (MDD) was more prevalent in the VaD group than in the AD group (20.4% in VaD, 10.2% in AD, p = 0.04, Cochran-Mantel-Haenszel, CMH, test) regardless of the dementia severity and gender. The odds ratio for developing MDD in the VaD group versus the AD group was estimated to be 2.20 (95% confidence interval = 1.02–4.74). Neurovegetative symptoms such as ‘felt tired and weak all the time’ (30.6% in VaD, 13.9% in AD, p = 0.003, CMH test) and ‘changed weight without trying’ (16.7% in VaD, 6.5% in AD, p = 0.02, CMH test) were more prevalent in the VaD group than in the AD group. Conclusion: Depression in VaD was quantitatively and qualitatively different from that in AD regardless of the severity of dementia and gender; depression was more prevalent, severer and more retarded and vegetative in VaD than in AD.

© 2007 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: September 20, 2006
Published online: November 15, 2006
Issue release date: January 2007

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.